› 4o8f

X-ray diffraction
2.6Å resolution

Crystal Structure of the complex between PPARgamma mutant R357A and rosiglitazone

Released:
DOI: 10.2210/pdb4o8f/pdb
PDB entry 4o8f coloured by chain, front view.
PDB entry 4o8f coloured by chain, side view.
PDB entry 4o8f coloured by chain, top view.
Source organism: Homo sapiens
Primary publication:
Structural basis of the transactivation deficiency of the human PPARĪ³ F360L mutant associated with familial partial lipodystrophy.
Lori C, Pasquo A, Montanari R, Capelli D, Consalvi V, Chiaraluce R, Cervoni L, Loiodice F, Laghezza A, Aschi M, Giorgi A, Pochetti G
Acta Crystallogr D Biol Crystallogr 70 1965-76 (2014)
PMID: 25004973

Function and Biology Details

Biochemical function:
Biological process:
Cellular component:
Sequence domains:

Structure analysis Details

Assemblies composition:
homo dimer
monomeric (preferred)
Assembly name:
PDBe Complex ID:
PDB-CPX-153368 (preferred)
Entry contents:
1 distinct polypeptide molecule
Macromolecule:
Peroxisome proliferator-activated receptor gamma Chains: A, B
Molecule details ›
Chains: A, B
Length: 287 amino acids
Theoretical weight: 32.61 KDa
Source organism: Homo sapiens
Expression system: Escherichia coli BL21
UniProt:
  • Canonical: P37231 (Residues: 223-505; Coverage: 56%)
Gene names: NR1C3, PPARG
Sequence domains: Ligand-binding domain of nuclear hormone receptor
Structure domains: Retinoid X Receptor

Ligands and Environments

1 bound ligand:
Ligand BRL 2 x BRL
No modified residues

Experiments and Validation Details

Entry percentile scores
X-ray source: ESRF BEAMLINE ID29
Spacegroup: C2221
Unit cell:
a: 85.7Å b: 87.1Å c: 163.8Å
α: 90° β: 90° γ: 90°
R-values:
R R work R free
0.24 0.234 0.297
Expression system: Escherichia coli BL21

Quick links

Citations

1 review citation

Structural and physico-chemical effects of disease and non-disease nsSNPs on proteins.
Kucukkal et al. (2015)
6 other articles

4 mentions without citation

Development of Heterocyclic PPAR Ligands for Potential Therapeutic Applications.
Virendra et al. (2022)
3 more